Cingulate Q1 net loss widens more than expected on commercial preparations

Cingulate

14/05/2026 13:12

Overview

U.S. biopharma company's Q1 net loss widened and missed analyst expectations

Net loss increase driven by higher G&A expenses for CTx-1301 commercial readiness

Company raised $12 mln in private placement, boosting cash and working capital

Outlook

Company expects current resources to fund operations into 2027

Cingulate continues to engage with FDA on CTx-1301 approval process

Company advancing commercial readiness and manufacturing for potential CTx-1301 launch

Result Drivers

COMMERCIAL PREPARATIONS - Higher G&A expenses driven by build-out of commercial infrastructure for CTx-1301 launch, including increased headcount

R&D SHIFT - Decrease in R&D expenses due to lower clinical operations costs as study activities concluded, offset by increased regulatory and manufacturing activities for NDA review

Company press release: ID:nGNX44Mv4H

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
Miss
-$9.31 mln
-$4.71 mln (3 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Cingulate Inc is $24.50, about 398% above its May 13 closing price of $4.92

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)